Background: Aspirin-exacerbated respiratory disease (AERD) is characterized by asthma, recurrent nasal polyposis, and respiratory reactions on ingestion of COX-1 inhibitors. Increased numbers of platelet-leukocyte aggregates are present in the sinus tissue and blood of patients with AERD compared with that of aspirin-tolerant patients, and platelet activation can contribute to aspirin-induced reactions. Objective: We sought to determine whether treatment with prasugrel, which inhibits platelet activation by blocking the type 12 purinergic (P2Y 12 ) receptor, would attenuate the severity of sinonasal and respiratory symptoms induced during aspirin challenge in patients with AERD. Methods: Forty patients with AERD completed a 10-week, doubleblind, placebo-controlled crossover trial of prasugrel. All patients underwent oral aspirin challenges after 4 weeks of prasugrel and after 4 weeks of placebo. The primary outcome was a change in the provocative dose of aspirin that would elicit an increase in Total Nasal Symptom Score (TNSS) of 2 points. Changes in lung function, urinary eicosanoids, plasma tryptase, platelet-leukocyte aggregates, and platelet activation were also recorded. Results: Prasugrel did not significantly change the mean increase in TNSS of 2 points (79 6 15 for patients receiving placebo and 139 6 32 for patients receiving prasugrel, P 5 .10),
platelet-leukocyte aggregates, or increases in urinary leukotriene E 4 and prostaglandin D 2 metabolite levels during aspirin-induced reactions in the study population as a whole. Five subjects (responders) reacted to aspirin while receiving placebo but did not have any reaction to aspirin challenge after the prasugrel arm. In contrast to prasugrel nonresponders (35 subjects), the prasugrel responders had smaller reactioninduced increases in TNSS; did not have significant aspirininduced increases in urinary leukotriene E 4 , prostaglandin D 2 metabolite, or thromboxane B 2 levels; and did not display increases in serum tryptase levels during aspirin reactions on the placebo arm, all of which were observed in the nonresponders. Conclusion: In the overall study population, prasugrel did not attenuate aspirin-induced symptoms, possibly because it failed to decrease the frequencies of platelet-adherent leukocytes or to diminish aspirin-induced mast cell activation. In a small subset of patients with AERD who had greater baseline platelet activation and milder upper respiratory symptoms during aspirin-induced reactions, P2Y 12 receptor antagonism with prasugrel completely inhibited all aspirin-induced reaction symptoms, suggesting a contribution from P2Y 12 Key words: Aspirin-exacerbated respiratory disease, double-blind, randomized, placebo-controlled crossover trial, prasugrel, Samter triad, NSAID-exacerbated respiratory disease, leukotrienes, P2Y 12 Aspirin-exacerbated respiratory disease (AERD) is a distinctive clinical syndrome affecting approximately 7% of adults with asthma and approximately 14% of those with severe asthma. 1 AERD is characterized clinically by asthma, rhinosinusitis with nasal polyposis, respiratory tissue eosinophilia, and respiratory reactions to ingestion of aspirin and other COX-1 inhibitors. Biochemically, AERD is marked by overactivity of the 5-lipoxygenase (5-LO)/leukotriene C 4 synthase (LTC 4 S) pathway, resulting in generation of high levels of leukotriene C 4 (LTC 4 ) and therefore high urinary levels of leukotriene E 4 (LTE 4 ), the stable end-product of cysteinyl leukotriene (CysLT) metabolism. CysLTs are powerful bronchoconstrictors and facilitate vascular leak and tissue eosinophilia. They play a major pathogenic role in patients with AERD, particularly in clinical reactions to aspirin challenge/desensitization. 2 Although eosinophils 3 and mast cells, 4 which express both 5-LO and LTC 4 S, likely account for the majority of CysLTs released in patients with AERD during clinical reactions, platelets can also play a role in CysLT overproduction. Platelets lack 5-LO 5 This conversion requires platelet activation and CD62P expression, resulting in CD62P-dependent adherence of platelets to 5-LO-expressing leukocytes (platelet-leukocyte aggregates). We have shown previously that both peripheral blood and sinonasal tissue of patients with AERD contain greater numbers of plateletleukocyte aggregates than do aspirin-tolerant patients and that their numbers correlate with basal urinary LTE 4 levels. 6 Moreover, mouse studies implicate platelet-leukocyte aggregates in CysLT generation during reactions to aspirin. 7 These observations suggest that agents capable of interfering with the formation of platelet-leukocyte aggregates could have therapeutic efficacy in patients with AERD. Based on these findings, we hypothesized that antiplatelet therapy might be efficacious in patients with AERD, particularly if it interferes with transcellular generation of LTC 4 .
Many stimuli that activate platelets elicit their release of adenosine diphosphate, which signals through the type 12 purinergic (P2Y 12 ) receptor to amplify CD62P expression and the interaction of platelets with leukocytes. Thienopyridine drugs (prasugrel and clopidogrel) that block P2Y 12 receptors inhibit platelet activation in patients with cardiovascular disease. 8 This double-blind, placebo-controlled trial aimed to test the hypothesis that blockade of P2Y 12 receptors with prasugrel would attenuate the severity of sinonasal and respiratory symptoms that occur during aspirin challenges in patients with AERD by blocking platelet activation and reducing CysLT generation by decreasing the frequency of platelet-leukocyte aggregates.
METHODS

Study design
Participants were enrolled in a 10-week, double-blind, placebo-controlled crossover trial of prasugrel. Each treatment arm lasted 4 weeks, with a 2-week washout phase in between. An oral aspirin challenge was conducted at the end of each treatment arm (Fig 1) . In a separate continuation study patients continued onto treatment with high-dose aspirin (650 mg twice daily).
Participants
Patients with AERD had a history of physician-diagnosed asthma, nasal polyposis, and at least 1 clinical reaction to aspirin or another nonselective COX inhibitor, with features of lower and/or upper airway involvement. They had refractory AERD with respiratory symptoms, which were not adequately responsive to other standard therapies, including corticosteroids and leukotriene modifiers, thus qualifying for aspirin desensitization and treatment with high-dose aspirin. Subjects had stable asthma, which was defined as a postbronchodilator FEV 1 of 70% of predicted value or greater; no increase in baseline dose of oral glucocorticoids for at least 3 months; and no history of hospitalization or emergency department visits because of asthma for at least 6 months before enrolling in the study to ensure the successful and safe completion of the protocol.
Subjects were excluded if they had current severe gastroesophageal reflux disease or a history of peptic ulcer disease or gastrointestinal bleed. All subjects were between the ages of 18 and 65 years and were not pregnant, breast-feeding, or smoking while participating in the trial.
This was a single-site study conducted at the Asthma Research Center, Brigham and Women's Hospital, Boston, Massachusetts. The Institutional Review Board of Brigham and Women's Hospital/Partners Healthcare approved this study, and all subjects provided written informed consent. Patients were recruited from August 2012 through April 2016, with the last patient's final visit in December 2016. The trial ended when recruitment goals were met. Compliance with montelukast and daily study drug administration was confirmed with both diary cards and pill counts.
Clinical procedures
After a 4-week run-in period on stable asthma treatment and 10 mg/d montelukast, subjects were randomized to begin taking either prasugrel (5 mg/d for patients weighing <60 kg or 10 mg/d for patients weighing > _60 kg after a 60-mg loading dose) or equivalent placebo for 4 weeks, followed by a 4-dose aspirin challenge (40.5, 81, 162, and 325 mg) with 90-minute intervals, 9 which was terminated when patients experienced either an increase in Total Nasal Symptom Score (TNSS) of at least 2 greter than baseline values or a decrease in FEV 1 of at least 15% from baseline or reached a dose of 325 mg of aspirin without any reaction symptoms. The TNSS questionnaire is a 9-symptom patient-recorded outcome measurement on a total scale of 0 to 40, which includes assessment of nasal congestion, runny nose, sneezing, nasal itching, and eye and throat symptoms (see Fig E1 in this article's Online Repository at www.jacionline.org for the full questionnaire). Baseline assessments were collected the morning of the aspirin challenge. Patients were observed for a 3-hour period after onset of their reaction and challenge termination, with serial measurements of lung function and TNSSs and collection of blood and urine samples. Subjects were discharged to home to continue daily montelukast and wash out the study drug from the first treatment phase. At the end of the 2-week washout period, subjects crossed over to alternate treatment for 4 weeks and returned for the second aspirin challenge, which proceeded as above.
Laboratory procedures
Blood was drawn into heparinized tubes, kept at room temperature, and assayed within 1 hour of collection. For aspirin challenge visits, blood was drawn in the morning before administration of aspirin and 1 hour after onset of the aspirin-induced reaction. If no reaction occurred, blood was drawn again 3 hours after the 325-mg dose of aspirin. Platelet-rich plasma (PRP) was obtained from the top layer of blood samples after a 20-minute centrifugation at 200g.
To monitor platelet activation and quantify platelet-leukocyte aggregates, we incubated 10 mL of PRP with directly conjugated antibodies specific for CD61 and CD62P and 20 mL of whole blood with antibodies specific for CD61, CD45, CD14, and CCR3 or appropriate isotype controls for 20 minutes; CCR3 antibody was from BioLegend (San Diego, Calif), and all others were from BD Biosciences (San Jose, Calif was determined based on relative expression of CD61 on each cell type. An aliquot of plasma from each blood draw was also analyzed at Virginia Commonwealth University for total tryptase levels. Levels of urinary eicosanoids were measured by using gas chromatography2mass spectrometry at Vanderbilt University, as previously described. 6 For aspirin challenge visits, urine samples were collected in the morning before aspirin administration and again at the onset of and 90 and 180 minutes after the aspirin-induced reaction. For those visits, during which no reaction was elicited, urine was collected 180 minutes after the 325-mg dose of aspirin.
DNA from peripheral blood leukocytes was used to sequence the P2RY12 locus (gene encoding the P2Y 12 receptor) in 28 subjects. DNA was extracted with an AllPrep DNA/RNA Mini Kit (Qiagen, Valencia, Calif). Five overlapping PCR amplicons covering the entire gene were sequenced by using the Illumina MiSeq platform (Illumina, San Diego, Calif) to generate 300-bp end reads, which were aligned to the reference human genome (GRCh37/hg19) using Bowtie2 (version 2.2.6). SAM tools (version 1.4) were used to call genetic variants from sorted and indexed BAM files. Association testing of genotype with response to prasugrel was performed by means of logistic regression on selected single nucleotide polymorphisms.
Outcomes
Because all subjects received montelukast throughout the study (which substantially attenuates aspirin-induced decreases in lung function), we used changes in nasal symptoms as the main indicator of reaction. The primary outcome compared the effect of 4 weeks of prasugrel versus placebo on the provocative dose that caused an increase in TNSS of 2 points (PD 2 ) during an aspirin challenge. PD 2 is modeled after the aspirin PD 20 Participants who did not have any clinically apparent reaction to aspirin during an aspirin challenge (a decrease in FEV 1 of <15% and no significant development of any naso-ocular or nonrespiratory symptoms, as quantified by the lack of increase in TNSS) were designated as having a negative challenge and were assigned a PD 2 of 650, which is double the maximum dose of aspirin given during either challenge.
Secondary outcomes included differences in provocative dose of aspirin, maximum increase in TNSS, change in urinary eicosanoid level, and platelet activation during aspirin challenge while receiving prasugrel versus placebo. Additional predefined outcomes included the effect of prasugrel on chronic asthma control, urinary eicosanoid metabolite levels, platelet activation, and fraction of exhaled nitric oxide (FENO) values in patients with AERD.
Sample size
The study was powered to detect an effect of prasugrel on PD 2 during aspirin desensitization. The sample size of 40 using a 2-sided paired t test comparing the mean PD 2 value between treatment with prasugrel and placebo provided 80% power to detect a 1.74-fold (0.8 after log 2 transformation) change in PD 2 at a .05 level of significance.
Randomization
Randomization consisted of 3 randomly selected blocks for each stratum of dose (5 or 10 mg) with a block size of 5 patients randomly assigned to treatment or control groups for each randomly selected block. We used permuted block randomization with SAS software (Version 9.2; SAS Institute, Cary, NC) proc plan, ensuring equal numbers of patients with AERD were randomized to each group. The Brigham and Women's Hospital Investigational Drug Services pharmacy conducted the randomization and kept the records to maintain the blind of the study. The Investigational Drug Services pharmacy also prepared the placebo and prasugrel through encapsulation.
Blinding
All participants, clinical care providers, and research staff were kept blind to intervention, and all analyses of mechanistic data (eg, flow cytometric measurements of platelet activation and urinary eicosanoid measurements) were completed before unblinding of research investigators.
Statistical methods
For the crossover study, we compared the difference in PD 2 values between the 2 (prasugrel vs placebo) aspirin challenges by using a 2-sided paired t test as the main comparison and used the same analysis for the change in maximum reduction in FEV 1 during aspirin reaction. We used mixed-model diagnostics, such as residual plots for goodness of fit, and before undertaking the primary analysis, we checked for a period effect. We compared levels of urinary LTE 4 and prostaglandin (PG) metabolites measured during the reaction to aspirin for subjects in both treatment arms, each separately by using a paired t test. We compared both the preaspirin baseline and the aspirin reaction-induced percentages of activated platelets and platelet-leukocyte aggregates for subjects pretreated with prasugrel and placebo, each by using a 2-sided paired t test. For the additional post hoc analyses done on the responder versus nonresponder subgroups, the false discovery rate method was used to correct for multiple comparison testing, with a rate greater than .05 considered significant. 11 Raw P values are presented, and significant values using the false discovery rate. Data are presented as 6 SEs, unless inverselog 10 ð22ðPrevTNSS2BaselineTNSSÞÞ3ðlog 10 ProvocDose2log 10 PrevDoseÞ ðMaxTNSS2BaselineTNSSÞ2ðPrevTNSS2BaselineTNSSÞ 1ðlog 10 PrevDoseÞ :
otherwise specified. This study was registered at clinicaltrials.gov as NCT01597375.
RESULTS Patients
A total of 51 potential participants were screened, 46 of whom underwent randomization per protocol, and 40 of whom completed the trial and were analyzed (Fig 2) . The baseline characteristics of the patients who underwent randomization are summarized in Table I . Thirty-nine of 40 patients had confirmed (diary cards and pill counts) compliance with both daily montelukast and daily study drug of greater than 90%.
Primary outcome
The mean PD 2 value in the prasugrel arm was 79 6 15, and the mean PD 2 value in the placebo arm was 139 6 32 (P 5 .10; Fig 3, A) . Of the 40 patients with AERD who completed the crossover trial, 5 did not have any clinically apparent reaction to aspirin during the arm when they had been treated with prasugrel (prasugrel responders) and were assigned a PD 2 value of 650. The clinical reactions of the 5 responders during the placebo arm challenge showed significantly smaller increases in TNSS compared with those of the 35 nonresponders (maximum TNSS increase, 3.4 6 0.8 for 5 responders vs 7.5 6 0.9 for 35 nonresponders; P 5 .003), although the average decrease in FEV 1 was similar (9.9% 6 3.5% vs 12.8% 6 2.0%, P 5 .50).
There was also 1 patient who did not have any clinically apparent reaction to aspirin during the placebo arm but did have a reaction during the prasugrel arm.
For the entire study population, the mean difference in maximum increase in TNSS for patients in the prasugrel arm compared with the placebo arm was 0.5 6 1.0 (P 5 .32), with a mean increase in TNSS on the prasugrel arm of 6.5 6 0.8 and a mean increase in TNSS on the placebo arm of 7.0 6 0.8 (Fig 3, B) . The administered aspirin dose that provoked a reaction for patients in the prasugrel arm was 0.2 6 0.22fold greater (P 5 .38) than the administered provocative aspirin dose for patients on the placebo arm.
Secondary outcomes
Treatment with prasugrel did not alter baseline percentages of CD62P
1 platelets compared with percentages after placebo in all 40 patients with AERD who completed the trial and did not change the percentages of any leukocyte subset with adherent platelets (Fig 4, A-E) . In the 40 patients as a group, neither the percentages of CD62P 1 platelets nor the percentages of leukocytes with adherent platelets changed 1 hour into aspirininduced reactions, and prasugrel did not alter these percentages when compared with placebo (Fig 4, A-E) . Plasma tryptase levels increased significantly during aspirin-induced reactions (increase of 44% 6 12% for the placebo arm [P 5 .02] and 60% 6 21% for the prasugrel arm [P 5 .004]), although treatment with prasugrel did not alter either the preaspirin levels of tryptase or the aspirin-induced increases (Fig 4, F) . A-D, Percentages of leukocytes with adherent platelets (as determined by staining with CD61) before aspirin (ASA) administration (solid columns) and 1 hour after reaction onset (striped columns) are shown for each treatment arm for eosinophils (Fig 4, A) , neutrophils (Fig 4, B) , monocytes (Fig 4, C) , and lymphocytes (Fig 4, D) . E and F, Percentages of platelets that expressed surface CD62P (Fig 4, E) and total plasma tryptase levels (Fig 4, F) are shown at the same time points. Data are expressed as means 1 SEs.
Prasugrel did not alter baseline levels of urinary eicosanoids measured before aspirin administration (Fig 5) . Urinary eicosanoid levels for patients receiving prasugrel treatment increased during aspirin-induced reactions to the same extent as those in patients receiving placebo treatment.
Characteristics of responder/nonresponder subgroups
The 5 prasugrel responders did not differ from the 35 nonresponders in terms of baseline demographics, Asthma Control Questionnaire scores, FEV 1 , TNSSs, FENO values, or preaspirin differential cell counts during either the prasugrel or placebo treatment arms, and their PD 2 values during the placebo arm challenge also did not differ (see Table E1 in this article's Online Repository at www.jacionline.org). The 5 responders had lower preaspirin baseline urinary levels of LTE 4 (0.14 6 0.03 vs 0.44 6 0.14 ng/mg creatinine [Cr], P 5 .042) and thromboxane B 2 (TXB 2 ; 0.26 6 0.03 vs 0.38 6 0.03 ng/mg Cr, P 5 .022) while receiving placebo compared with the 35 nonresponders and tended to show reduced prostaglandin D 2 metabolite (PGD-M) levels (1.73 6 0.20 vs 2.35 6 0.26 ng/mg Cr, P 5 .067). Responders had significantly lower peak levels of urinary LTE 4 (0.46 6 0.20 vs 9.91 6 2.50 ng/mg Cr, P 5 .0009), PGD-M (2.11 6 0.50 vs 10.37 6 2.97 ng/mg Cr, P 5 .011), and TXB 2 (0.19 6 0.04 vs 0.53 6 0.08 ng/mg Cr, P 5.001) in response to aspirin challenge (Fig 6, A-C) . Compared with baseline prechallenge levels, responders showed no significant aspirin-induced increases in urinary LTE 4 (Fig 6, A) or PGD-M (Fig 6, B) levels. Furthermore, although there was a clear aspirin-induced increase in plasma tryptase levels 1 hour into the aspirin-induced reactions in the 35 nonresponders (increase of 52% 6 14% for the placebo arm, P 5 .004), the 5 responders trended toward a slight decrease in plasma tryptase levels (change of -9% 6 4%, P 5 .112) during their placebo arm aspirin challenge, with a significant difference in aspirin-induced change in tryptase levels between the 2 groups (P 5 .001; Fig 6, D) . The maximum increase in TNSS during the placebo arm challenges correlated with the fold increase in urinary LTE 4 levels (r 5 0.58, P 5 .001), with a trend toward an increase in TNSS correlations with the increase in urinary PGD-M and serum tryptase levels.
Peripheral blood absolute eosinophil count decreased in the 35 nonresponders during the aspirin-induced reaction in the placebo arm (2155 6 41 cells/mL) but did not change in the responders (140 6 68 cells/mL, P 5 .043). Although their baseline eosinophil numbers did not differ, the 5 responders had significantly higher percentages of eosinophils with platelets attached than did the nonresponders at the preaspirin baselines while in the prasugrel arm (62% 6 5% vs 40% 6 5%, P 5 .001; Fig 7, A) . The 5 responders also had a trend toward prasugrel-induced decrease in preaspirin baseline activated platelet (CD62P 1 platelet) counts in the prasugrel treatment arm compared with the placebo arm (reduction from 38% 6 5% on placebo to 25% 6 3% on prasugrel, P 5 .046), although this difference was not significant when corrected for multiple comparison testing. In contrast, prasugrel treatment did not lead to a decrease in platelet activation for the nonresponders (Fig 7, B) .
Urine collected 3 hours after the 325-mg dose of aspirin from the patients who did not manifest any reaction is not biologically equivalent in time point or dose to that collected during aspirin-induced reactions. However, we analyzed these samples for eicosanoid levels from the 4 patients from whom they were collected. The change in urinary LTE 4 and urinary PGD-M levels (preaspirin baseline to 3 hours after 325 mg) during the prasugrel arm did not differ from the change (preaspirin baseline to 3 hours after reaction) measured during the placebo arm nor did the We conducted a post hoc analysis of P2RY12 sequencing of the 5 responders and 23 nonresponders for whom we had sufficient genomic DNA. Of the 26 selected single nucleotide polymorphisms, 19 of which were previously associated with P2RY12 gene expression, 2 were exonic, 23 were intronic, and 1 was upstream of the gene. No variant was predicted to disrupt amino acid composition, and none were associated with drug response (see Table E2 in this article's Online Repository at www.jacionline.org).
Safety
The number of total and severe adverse events was similar between the placebo and prasugrel arms (see Table E3 in this article's Online Repository at www.jacionline.org). Prasugrel was associated with a higher likelihood of bruising (P 5 .006). No patients withdrew participation because of any prasugrelrelated adverse events. One patient withdrew participation after the first aspirin challenge, which had been during the placebo arm, because of a systemic reaction to the aspirin challenge that included vomiting.
DISCUSSION
Aberrantly increased CysLT production, eosinophilic respiratory tract inflammation, and persistent mast cell activation are all steady-state features of AERD that are further amplified during reactions to drugs that block COX-1. These reactions are thought to involve a prominent contribution from CysLTs and mast cell-derived mediators. We 6 and others 12 have demonstrated increased numbers of platelet-leukocyte complexes in the blood of patients with AERD and also observed such complexes in sinonasal tissues. 6 The CD62P-dependent adherence of platelets to leukocytes has several physiologic consequences, including transcellular conversion of leukotriene A 4 to LTC 4 by platelets. 5, 13 Adherent platelets accounted for the majority of LTC 4 S activity of blood granulocyte fractions from patients with AERD. 6 Platelets were also necessary for the surge of CysLT generation induced by aspirin challenge in AERD-like mice. 6, 7 We aimed to determine whether a similar platelet-dependent mechanism contributed to the aspirin-induced symptoms in patients with AERD. A previous study suggested that 6 days of treatment with clopidogrel, a thienopyridine antagonist of the P2Y 12 receptor, reduced numbers of platelet-monocyte aggregates in the blood of healthy patients.
14 Therefore we conducted this crossover study to determine whether prasugrel could block CysLT-dependent reactions to aspirin challenge and inhibit the formation of platelet-leukocyte aggregates in well-characterized patients with AERD.
Along with sinonasal congestion and ocular symptoms, reactions to aspirin in patients with AERD frequently result in sharp reductions in FEV 1 . These reductions in part reflect the actions of CysLTs at the type 1 CysLT receptor (CysLT 1 R). To ensure the safety of the challenges in this study, all subjects were treated with montelukast, an inhibitor of CysLT 1 R, during challenge. CysLT 1 R blockade attenuates the decrease in lung function induced by aspirin but does not tend to eliminate the upper respiratory tract symptoms indicative of a reaction. 15 Therefore we used TNSS, rather than a change in FEV 1 , as the basis for assessing reactions, and calculated the PD 2 value for aspirin on prasugrel versus placebo as the primary outcome based on TNSS. (Fig 6, A) , PGD-M (Fig 6, B) , and TXB 2 (Fig 6, C) before aspirin administration (white columns) and at the aspirin reaction-induced peak (striped columns) are shown for the responders (blue lines) and nonresponders. D, Placebo arm plasma tryptase levels before aspirin administration and 1 hour after the reaction onset are shown for the same patient subgroups. Data are expressed as means 1 SEs. P values marked with asterisks are significant by using a false discovery rate of .05 to correct for multiple comparisons.
All 40 subjects experienced characteristic reactions on at least 1 of the 2 challenges, and most reacted to both challenges, confirming their diagnosis of AERD. Although treatment with prasugrel increased PD 2 values, this did not reach significance (P 5.10, Fig 3) . Moreover, in the population of patients as whole, prasugrel did not alter the baseline TNSS or Asthma Control Questionnaire score, baseline urinary eicosanoid level, FENO value, or change in eicosanoid level with aspirin challenge. In general, the maximum decrease in FEV 1 during aspirin-induced reactions correlated with the maximum increase in TNSS (r 5 0.50, P 5 .001; see Fig E4 in this article's Online Repository at www.jacionline.org). Of the 74 aspirin-induced reactions in the study, 28 of those involved a decrease in FEV 1 of 15% or greater (38% of the reactions), which is consistent with previous reports of the rates of lower respiratory tract symptoms. 15 As previously reported, CD62P
1 -free platelets (Fig 4, A) and platelet-leukocyte aggregates (Fig 4, B-D) were readily detectable in the blood of all subjects and did not change with aspirin challenge. 6, 12 As expected, mean urinary LTE 4 levels increased sharply during reactions for the group as a whole (Fig 5) along with metabolite levels of PGD 2 , the dominant COX product of mast cells, and plasma tryptase levels, which are all potential or verified indices of mast cell activation.
Five of the 40 subjects reacted while receiving placebo but did not exhibit any signs or symptoms of an aspirin-induced reaction (neither TNSS increase of > _2 points nor FEV 1 decrease of > _15%) while receiving prasugrel. Although the PD 2 value and the change in FEV 1 in responders were similar to the remainder of the cohort, the severity of upper respiratory symptoms, as measured by maximum increase in TNSS, was significantly milder in responders than in nonresponders (see Table E1 ).
Several features suggest that responders could represent an endotype of AERD with mild upper respiratory reactions. First, the baseline fraction of blood eosinophils with adherent platelets in the responder subgroup significantly exceeded those in nonresponders. This did not change as a result of prasugrel treatment (Fig 7, A) . Second, in marked contrast to the nonresponders, responders did not display significant aspirin-induced increases in urinary LTE 4 , PGD-M, and TXB 2 levels or aspirin-induced increases in plasma tryptase levels (all of which reflect mast cell activation; Fig 6) 16,17 during reactions on the placebo arm. Finally, blood eosinophil numbers decreased significantly during reactions on the placebo arm in the 35 nonresponders (presumably reflecting their recruitment to the respiratory tissue) 18, 19 but not in the responders. Both LTE 4 20 and PGD 2 21 recruit eosinophils to the respiratory tissue. Thus the lack of change in blood eosinophil counts during reactions in the responder group could reflect low release of these lipid mediators by tissue mast cells. Collectively, our findings strongly suggest a small group of patients with AERD whose relatively low levels of mast cell mediator release reveal a P2Y 12 -mediated component of their aspirin-induced reactions. This work, in conjunction with previous reports of a highly PGD 2 -driven subgroup, confirms that multiple endotypes exist within the AERD phenotype of asthma. Our previous studies and those of others demonstrated that baseline blood platelet activation in patients with AERD exceeds that found in aspirin-tolerant control subjects by several fold. 6, 12 Given that P2Y 12 receptors are required for autocrine activation of platelets in response to several classical agonists, it is surprising that prasugrel did not alter platelet CD62P levels in the entire cohort and did not change the percentages of platelet-leukocyte aggregates. Thus aberrant levels of steady-state platelet activation in patients with AERD might be driven by mechanisms that do not require P2Y 12 -dependent amplification. Because P2Y 12 receptors are also expressed by M2-type macrophages, 22 dendritic cells, 23 and eosinophils, 24 it is possible that cell types other than platelets contribute to the reactions in the responder group. Polymorphic variants of the P2RY12 gene have been associated with the risk of airway obstruction in house dust mite-sensitized children 25 and with indices of platelet and eosinophil activation in patients with AERD. 26 Although our identification of a responder subgroup of patients with AERD suggests a potential genetic mechanism, we did not identify any P2RY12 variants that distinguished the 2 groups.
Because the mechanism by which platelet activation occurs in patients with AERD does not appear to require the P2Y 12 receptor amplification loop (except for the responder subgroup), our study can neither verify nor refute the potential role of platelets in facilitating leukocyte adhesion and recruitment or transcellular synthesis of LTC 4 in patients with AERD. Determining the mechanism responsible for AERD-associated platelet activation will be necessary to address this role by using a different target for intervention. Although prasugrel treatment is not effective for most patients with AERD, this study uncovered a potential subset of patients with AERD whose aspirin-induced reactions might involve P2Y 12 receptors, potentially because of reduced mast cell mediator release. Future larger studies will be necessary to validate this observation and reveal mechanisms. All events that occurred after randomization through 2 weeks after the second aspirin challenge were included. Data listed are the number of participants reporting each type of adverse event.
NSAID, Nonsteroidal anti-inflammatory drug.
